For FY17, IPH Ltd reported Change in patent filing trend

Change in patent filing trend: For FY17, IPH Ltd reported (ASX: IPH) an 11% yoy (year on year) growth in statutory Net Profit after Tax (NPAT) at $42.9m, that yields diluted earnings of 22.3c/share. The underlying NPAT for the year increased by 9% to $51.2m over the previous corresponding period. Excluding the impact of the further investment in the Data and Analytics software division, the diluted EPS grew by 8% on a statutory basis and 6% on an underlying basis. Underlying EBITDA increased by 10% on the corresponding period to $71.6M. However, the strengthening of the AUD relative to the USD in June led to the recognising of unrealised exchange losses on the revaluation of USD dominated cash and receivables balances of approximately $700k. IPH further stated that applying an AUD/USD exchange rate of 76.2c as provided with the company’s EBITDA guidance of $72M-$74M in November, the reported underlying EBITDA would have been more than $72m and within guidance range.

To read the complete report CLICK HERE. To get your free report CLICK HERE

2016 ALL ORDINARIES ASX Mid Cap Stocks ASX200 Australian Mid-Cap Dividend Stocks S&P/ASX 200 S&P/ASX 200 Industrials S&P/ASX 300 S&P/ASX All Australian 200 S&P/ASX SMALL ORDINARIES Uncategorized

For 1HFY17, Iress Ltd Earnings impacted by one-off costs and currency movements

Earnings impacted by one-off costs and currency movements: For 1HFY17, Iress Ltd (ASX: IRE) has reported a statutory net profit after tax of $29.5 million, up 10% over the previous half (six months to 31 December 2016) and down 10% over the prior corresponding period (six months to 30 June 2016). NPAT performance difference between corresponding halves reflects the impact of non-recurring items, movements in currency, amortisation charges on recently-acquired business and movements in interest and tax charges. Operating revenue increased to $211.8 million, up 8% on 2H16 and 9% on 1H16. Importantly, segment declined marginally to $59.6 million, down 1% on 2H16 (down 2% on a constant currency basis against 2H16) and down 6% on 1H16 (down 3% on a constant currency basis against 1H16) due to one off costs associated with client and internal people activities. Excluding these one-off costs, segment profit would have been up 3% on the previous half. Cashflow conversion remained high at 91%, in line with the previous half. The impact of currency movements on revenue and segment profit over the prior corresponding period was quite visible.

To read the complete report CLICK HERE. To get your free report CLICK HERE

2016 ALL ORDINARIES ASX Mid Cap Stocks ASX200 Australian Mid-Cap Dividend Stocks S&P/ASX 200 S&P/ASX 200 Information Technology S&P/ASX 300 S&P/ASX All Australian 200 S&P/ASX SMALL ORDINARIES Uncategorized

2 Stocks that slipped on ASX – Iress Ltd and IPH Ltd

Earnings impacted by one-off costs and currency movements: For 1HFY17, Iress Ltd (ASX: IRE) has reported a statutory net profit after tax of $29.5 million, up 10% over the previous half (six months to 31 December 2016) and down 10% over the prior corresponding period (six months to 30 June 2016). NPAT performance difference between corresponding halves reflects the impact of non-recurring items, movements in currency, amortisation charges on recently-acquired business and movements in interest and tax charges. Operating revenue increased to $211.8 million, up 8% on 2H16 and 9% on 1H16. Importantly, segment declined marginally to $59.6 million, down 1% on 2H16 (down 2% on a constant currency basis against 2H16) and down 6% on 1H16 (down 3% on a constant currency basis against 1H16) due to one off costs associated with client and internal people activities. Excluding these one-off costs, segment profit would have been up 3% on the previous half. Cashflow conversion remained high at 91%, in line with the previous half. The impact of currency movements on revenue and segment profit over the prior corresponding period was quite visible.

 

To read the complete report CLICK HERE. To get your free report CLICK HERE

 

 

2016 ALL ORDINARIES ASX Mid Cap Stocks ASX200 Australian Mid-Cap Dividend Stocks S&P/ASX 200 S&P/ASX 200 Information Technology S&P/ASX 300 S&P/ASX All Australian 200 S&P/ASX SMALL ORDINARIES Uncategorized

Healthscope Ltd Sale of standalone medical centres operations

Sale of standalone medical centres operations: Healthscope Ltd (ASX: HSO) has entered into an agreement to sell its standalone medical centres operations for A$55 million to Fullerton Primary Care Pty Ltd (subsidiary of Fullerton Australia). The transaction is expected to be complete by the end of September 2017. Healthscope’s standalone medical centres operations consist of 43 medical centres, four specialist skin clinics and one specialist breast diagnostic clinic located across Victoria, New South Wales, the Australian Capital Territory, Queensland and Western Australia. In the first half of FY17, the standalone medical centres operations contributed approximately 2% of Group Operating EBITDA. Further, HSO expects to book a non-cash impairment loss of $54.7 million in relation to the sale to be recorded in the FY17 financial results. Divestment of the Medical Centres operations is part of its strategic review and it will allow the company to focus on core hospitals and international pathology operations. As part of the transaction, all existing medical centres employees will be offered continued employment with the business going forward.

To read the complete report CLICK HERE. To get your free report CLICK HERE


 

 

CLICK HERE

 

 

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
2016 ALL ORDINARIES ASX Mid Cap Stocks ASX100 ASX200 Australian Mid-Cap Dividend Stocks S&P/ASX 200 S&P/ASX 200 Health Care S&P/ASX 300 S&P/ASX All Australian 200 S&P/ASX MIDCAP 50 Uncategorized

What is the latest with these 2 healthcare stocks – Healthscope and Primary Health Care

Sale of standalone medical centres operations: Healthscope Ltd (ASX: HSO) has entered into an agreement to sell its standalone medical centres operations for A$55 million to Fullerton Primary Care Pty Ltd (subsidiary of Fullerton Australia). The transaction is expected to be complete by the end of September 2017. Healthscope’s standalone medical centres operations consist of 43 medical centres, four specialist skin clinics and one specialist breast diagnostic clinic located across Victoria, New South Wales, the Australian Capital Territory, Queensland and Western Australia. In the first half of FY17, the standalone medical centres operations contributed approximately 2% of Group Operating EBITDA. Further, HSO expects to book a non-cash impairment loss of $54.7 million in relation to the sale to be recorded in the FY17 financial results. Divestment of the Medical Centres operations is part of its strategic review and it will allow the company to focus on core hospitals and international pathology operations. As part of the transaction, all existing medical centres employees will be offered continued employment with the business going forward.

 

To read the complete report CLICK HERE. To get your free report CLICK HERE

2016 ALL ORDINARIES ASX Mid Cap Stocks ASX100 ASX200 Australian Mid-Cap Dividend Stocks S&P/ASX 200 S&P/ASX 200 Health Care S&P/ASX 300 S&P/ASX All Australian 200 S&P/ASX MIDCAP 50 Uncategorized

Total zircon/rutile/synthetic rutile Quarterly production update

Quarterly production update: Total zircon/rutile/synthetic rutile (Z/R/SR) production in the second quarter was 221 thousand tons inclusive of Sierra Rutile, with 177 thousand tonnes from Iluka’s Australian and US operations. The Tutunup South mine in south-west Western Australia continued to be Iluka’s only Australian mine in operation. During the quarter, 160 thousand tons of heavy mineral concentrate (HMC) was produced and 348 thousand tons processed globally. This reflected the continued draw down of HMC from the Jacinth- Ambrosia mine (currently idle) and the Woornack, Rownack, and Pirro mine (mining completed 2015). The company has announced in June the planned restart of mining at Jacinth-Ambrosia from December 2017, following the substantial draw down of HMC inventory. 

 

 

To read the complete report CLICK HERE. To get your free report CLICK HERE

2016 ALL ORDINARIES ASX Mid Cap Stocks ASX100 ASX200 ASX50 Australian Mid-Cap Dividend Stocks S&P/ASX 100 S&P/ASX 200 S&P/ASX 200 Materials S&P/ASX 200 RESOURCES S&P/ASX 300 S&P/ASX 300 Metals and Mining S&P/ASX All Australian 200 S&P/ASX All Australian 50 S&P/ASX MIDCAP 50 Uncategorized